Canaccord Genuity Reiterates Buy on 10x Genomics, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson has reiterated a 'Buy' rating on 10x Genomics (NASDAQ:TXG) and maintained a price target of $70.
September 19, 2023 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has reiterated a 'Buy' rating on 10x Genomics and maintained a price target of $70.
The reiteration of a 'Buy' rating by Canaccord Genuity indicates their continued confidence in 10x Genomics. The maintained price target of $70 suggests they believe the stock is still undervalued. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100